Rich by Coin

Hyperion DeFi, Inc., the first U.S. publicly listed DeFi company building on Hyperliquid, announced that it will hold its earnings conference call and webcast for the fourth quarter and full year ended December 31, 2025, on Thursday, March 26, 2026 at 8:00 a.m. Eastern Time. A press release detailing these results will be issued prior to the call on the same day.

Conference Call Information: Date March 26, 2026, Time 8:00 a.m. ET, Access ID 13758512. Webcast and dial-in options are available: Dial in 1-877-407-9039 or 1-201-689-8470, and the “Call me” link will be available 15 minutes prior to the scheduled start time. Replay Information: Dial-In 1-844-512-2921 or 1-412-317-6671, with replay expiration on Thursday, April 9, 2026, Access ID 13758512.

Hyperliquid is a next-generation layer one blockchain optimized for high frequency, transparent trading. The blockchain includes fully on-chain perpetual futures and spot order books, with every order, cancel, trade, and liquidation occurring within 70 millisecond block times. It also hosts the HyperEVM, a general-purpose smart contract platform that supports permissionless decentralized financial applications akin to Ethereum. HYPE is the native token of Hyperliquid.

Hyperion DeFi, Inc. is the first U.S. publicly listed DeFi company building on Hyperliquid. The Company provides investors with streamlined access to the Hyperliquid ecosystem, one of the fastest growing, highest revenue-generating blockchains in the world. Shareholders benefit from compounding exposure to HYPE, both from its native staking yield and additional revenues generated from its on-chain utility. For more information, please visit Hyperiondefi.com or follow @hyperiondefi on X.

Hyperion DeFi is also developing its proprietary Optejet User Filled Device that is designed to work with a variety of topical ophthalmic liquids, including artificial tears and lens rewetting products. The Optejet is especially useful in chronic front-of-the-eye diseases due to its ease of use, enhanced safety and tolerability, and potential for superior compliance versus standard eye drops. Together, these benefits may result in higher treatment compliance and better outcomes for patients and providers.